This study evaluated the effectiveness and long-term safety of dorzagliatin in patients with type 2 diabetes (T2D) without previous antidiabetic treatment. The authors concluded that dorzagliatin blood glucose (sugar) levels with no serious side effects in these patients. 

This study analyzed the safety and effectiveness of dapagliflozin (Farxiga) in patients with type 2 diabetes (T2D) across different ranges of baseline systolic blood pressure (SBP; blood pressure when the heart beats). The data suggested that dapagliflozin reduced the risk of hospitalization for heart failure (HHF) and kidney-related outcomes and was safe for use across different levels of SBP without causing an increase in short-term (acute) kidney injury, dehydration, or amputations in patients.

This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin (Jardiance) may protect against eye disease while canagliflozin (Invokana) may promote eye disease. 

This study evaluated the effectiveness and safety of low-intensity extracorporeal shock wave therapy (Li-ESWT) for patients with diabetes and erectile dysfunction (ED). The data showed that Li-ESWT was safe and effective in improving the symptoms of ED in these patients.

This review analyzed the effectiveness and safety of nutrient supplements for the control of blood glucose and insulin resistance in patients with type 2 diabetes (T2D). The authors concluded that there is currently a lack of sufficient clinical evidence to support the use of nutrient supplements for blood glucose control and improved insulin resistance in these patients.

This study evaluated the most effective and safe dose of dapagliflozin (Farxiga) as an additional treatment to insulin in patients with type 1 diabetes (T1D). The authors concluded that 10 mg of dapagliflozin as an add-on to insulin treatment resulted in improved blood glucose (sugar) control, reduced insulin dosage, and body weight without causing an elevated risk of low blood glucose in these patients.

This review assessed the effects of new glucose-lowering drugs on stroke risk in patients with type 2 diabetes (T2D). The study showed that glucagon-like peptide-1 receptor (GLP-1) agonists are potentially beneficial for stroke risk in patients with T2D.

This study evaluated the effectiveness of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with a vacuum erectile device (VED) for the treatment of patients with diabetes mellitus (DM) and erectile dysfunction (ED) who were unresponsive to phosphodiesterase-5 (PDE5) inhibitors. The data showed that Li-ESWT combined with VED was more effective than Li-ESWT or VED therapy alone for the treatment of these patients.

This study evaluated the effects of the plant-based polyphenol-rich extract TOTUM-63 on glucose control in patients with prediabetes or early-stage newly diagnosed type 2 diabetes (T2D). The data showed that TOTUM-63 was safe and lowered fasting blood glucose in these patients. 

This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated.